Tenax Therapeutics, Inc. (TENX)
US — Healthcare Sector
Automate Your Wheel Strategy on TENX
With Tiblio's Option Bot, you can configure your own wheel strategy including TENX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TENX
- Rev/Share 0.0
- Book/Share 2.9873
- PB 2.0286
- Debt/Equity 0.0
- CurrentRatio 40.4837
- ROIC 0.0358
- MktCap 25139849.0
- FreeCF/Share -0.4541
- PFCF -1.5133
- PE -9.1571
- Debt/Assets 0.0
- DivYield 0
- ROE -0.3151
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TENX | Guggenheim | -- | Buy | -- | $16 | Oct. 14, 2024 |
| Initiation | TENX | William Blair | -- | Outperform | -- | -- | Sept. 30, 2024 |
News
About Tenax Therapeutics, Inc. (TENX)
- IPO Date 1994-04-04
- Website https://www.tenaxthera.com
- Industry Biotechnology
- CEO Mr. Christopher T. Giordano
- Employees 4
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.